ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式(ヒル表記法):
C8H15N7O2S3
CAS番号:
分子量:
337.45
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Quality level:
製品名
ファモチジン,
Quality Level
originator
Johnson & Johnson
SMILES string
N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1
InChI
1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
InChI key
XUFQPHANEAPEMJ-UHFFFAOYSA-N
Gene Information
human ... HRH2(3274)
類似した製品をお探しですか? 訪問 製品比較ガイド
関連するカテゴリー
Application
Famotidine has been used to test its effect on the human ether-a-go-go-related gene (hERG) binding transfected in HEK293 membrane. It has also been used in polycaprolactone based drug delivery studies.
Biochem/physiol Actions
H2ヒスタミンレセプタ-のアンタゴニストであり、抗潰瘍薬です。
Famotidine is not effective on muscarinic and nicotinic receptors. It competitively inhibits the secretion of gastric acid and elicits mucosal injury protection.
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
保管分類
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Polycaprolactone thin-film drug delivery systems: empirical and predictive models for device design
Schlesinger E, et al.
Materials Science and Engineering, C, 57, 232-239 (2015)
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs
Taha AS, et al.
The New England Journal of Medicine, 334(22), 1435-1439 (1996)
Famotidine: an update review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied disease
Healther DL, et al.
Drugs, 38(3), 551-590 (2015)
Makoto Anraku et al.
International journal of pharmaceutics, 487(1-2), 142-147 (2015-04-18)
An intermolecular complex formed from a 1:1 weight ratio of chitosan (CS, molecular weight 30 kDa) and sulfobutyl ether β-cyclodextrin (SBE-β-CyD, degree of substitution 7) was less soluble than either of the original components. The release of famotidine from tablets
The [3H] dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+] o
Diaz GJ, et al.
Journal of Pharmacological and Toxicological Methods, 50(3), 187-199 (2004)
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)